

# ANCO FAX News

Association of Northern California Oncologists  
Post Office Box 151109, San Rafael, California 94915-1109  
Voice: (415) 472-3960 • FAX: (415) 472-3961  
ExecDir@anco-online.org • www.anco-online.org

Vol. 6, No. 7

April 6<sup>th</sup>, 2007

## INTRODUCTION

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, membership benefits, and *Association* news. While membership mailings, FAX broadcasts, and ListServ postings continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News* or to contribute items.

The *ANCO FAX News* is sent to member practices (via FAX) and Corporate Member contacts (via e-mail). The next regular *ANCO FAX News* will be published on April 20<sup>th</sup>. Comments on and contributions to the *ANCO FAX News* are always welcome and encouraged at ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; ExecDir@anco-online.org.

## ADVOCACY

[*Editor's Note:* ANCO meets regularly with national, regional, and statewide organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

### *ACCC, ASCO, ASH, and National Legislative & Regulatory Issues*

[*Editor's Note:* ANCO is a member of the *Association of Community Cancer Centers* (ACCC) and a state/regional affiliate of the *American Society of Clinical Oncology* (ASCO).

ANCO and the *American Society of Hematology* (ASH) share information with members. We regularly participate with these organizations on matters of national importance to cancer care.]

The *United States Food & Drug Administration* recently issued alerts and warnings for **erythropoiesis stimulating agents** (ESAs) reporting a higher risk of serious and life-threatening events associated with the use of ESAs in various clinical applications. In response, CMS initiated a *National Coverage Analysis* (NCA) to evaluate the use of these drugs in non-

**There is information in the  
ANCO FAX News  
for every member of your practice  
or organization.  
Pass it along!**

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

renal disease applications. The initial 30-day public comment period runs until April 13<sup>th</sup>. The NCA comment period allows all interested parties to comment on proposed decision memos, to seek clarification of posted information, to provide additional information that may be useful in the decision making process, and to provide informed opinions on the subject under consideration. When commenting to CMS include all relevant clinical studies and scientific information. To comment electronically visit [www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=203](http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=203) and click on the orange "Comment" box. Please note that these comments are directed at CMS policy making. NHIC/Medicare has already revised its ESA coverage policy (see below).

**A CMS 2007 Physician Quality Reporting Initiative (PQRI) webpage is now available.** It includes a revised PowerPoint presentation under the *Educational Resources* tab. PQRI establishes a financial incentive for eligible professionals to participate in a voluntary quality-reporting program. Eligible professionals who successfully report a designated set (at least three of a possible sixty-six in 80% of applicable cases) of quality measures on claims for dates of service from July 1<sup>st</sup> to December 31<sup>st</sup>, 2007, may earn a lump sum bonus payment in early 2008, subject to a cap, of 1.5% of total allowed charges for covered Medicare physician fee schedule services. You do not need to enroll to participate in the program. You must report the appropriate quality measure data on claims using G-codes and/or CPT codes (now available at [www.cms.hhs.gov/PQRI](http://www.cms.hhs.gov/PQRI); under the *Measures/Codes* tab; see more below). For more information on PQRI, visit [www.cms.hhs.gov/PQRI/01\\_Overview.asp#TopOfPage](http://www.cms.hhs.gov/PQRI/01_Overview.asp#TopOfPage). A *MLN Matters* article with important information on the 2007 PQRI is also available at [www.cms.hhs.gov/mlnmattersarticles/downloads/mm5558.pdf](http://www.cms.hhs.gov/mlnmattersarticles/downloads/mm5558.pdf). Listen to a replay of the March 27<sup>th</sup> national provider call on PQRI by calling (888) 348-4629 (passcode 549030); read a transcript by visiting [www.cms.hhs.gov/PQRI](http://www.cms.hhs.gov/PQRI); or, download the PowerPoint slides at [www.cms.hhs.gov/PQRI/30\\_EducationalResources.asp#TopOfPage](http://www.cms.hhs.gov/PQRI/30_EducationalResources.asp#TopOfPage).

**CMS has released detailed specifications for measures to be reported as part of the PQRI**

**program.** Measures that may be directly applicable to hematologists/oncologists include:

1. Hormonal therapy for Stage IC-III, ER/PR positive breast cancer.
2. Chemotherapy for Stage III colon cancer patients.
3. Documentation of a chemotherapy treatment plan prior to chemotherapy administration.
4. Baseline flow cytometry studies performed for CLL.
5. Intravenous bisphosphonate therapy for multiple myeloma.
6. Documentation of iron stores prior to initiating erythropoietin therapy for MDS.
7. Baseline cytogenetic testing performed on bone marrow for MDS or acute leukemia.

ASCO will develop additional educational resources for oncologists who are interested in participating in PQRI. ASCO also will continue to promote the use of measures that provide clinically meaningful data to reporting physicians.

**ASCO's *Practical Tips for the Oncology Practice, 4th Edition*, is now available.** The new edition answers the most commonly asked questions on coding, billing, and reimbursement of oncology-related services, and includes expanded discussions on billing requirements, nurse practitioners and physician assistants, Medicare Part D, and the laws and regulations affecting oncology offices. The publication can be purchased by contacting ASCO publications at [ascopubs@asco.org](mailto:ascopubs@asco.org) or calling (888) 273-3508. The book can also be purchased online at [www.asco.org](http://www.asco.org).

**ANCO and ASCO continue to work towards ensuring that people with cancer have access to quality cancer care in the community.** Practice resources are available at [www.anco-online.org](http://www.anco-online.org) and [www.asco.org/mma](http://www.asco.org/mma), including:

- ASCO's *Adapting to Changes in Medicare 2007* PowerPoint presentation.

- The April 2007 quarterly update for the *Average Sales Price* (ASP) Medicare Part B drugs pricing file.

Members may also call/e-mail ASCO's billing and coding hotline at (703) 299-1054/practice@asco.org for up-to-date information on changes in coding for drug administration services, as well as billing and payments for drugs.

### ***CMA, MOASC, and State Legislative & Regulatory Issues***

*[Editor's Note: ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) House of Delegates and Council on Legislation. ANCO and MOASC coordinate advocacy activities in California.]*

**Join the *California Breast Cancer Research Program* (CBCRP) at one of several upcoming stakeholder meetings to advise them on how to invest \$18M for the *Special Research Initiatives* focusing on environmental links to breast cancer and the unequal burden of the disease.** The next meeting is scheduled for San Francisco on April 11<sup>th</sup>; a telephone/web conference is scheduled for April 12<sup>th</sup>. Advocates, researchers, healthcare providers, and anyone interested in these issues are invited to attend. For more information and to register, visit [www.cabreastcancer.org/sri](http://www.cabreastcancer.org/sri) or call (888) 313-2277.

**CMA and county medical societies are cohosting a series of seminars to help physician practices assess payor contracts and prepare for contract negotiations.** *Taking Charge* seminars are scheduled as follows:

- April 14-15<sup>th</sup>, Monterey
- June 7-8<sup>th</sup>, Napa/Solano
- June 13<sup>th</sup>, Butte Glen (tentative)
- June 14<sup>th</sup>, North Valley (Chico)

Attendees will learn how to evaluate current and proposed payor contracts; target payors for contract termination, negotiation, or renegotiation; monitor payor compliance with contract terms; and, determine a payor's value to their practice. Participants will also receive a copy of CMA's payor contracting guide entitled *Taking Charge: Steps to Evaluating Relationships and Preparing for Negotiations*. Visit [www.calphys.org/html/cc270.asp](http://www.calphys.org/html/cc270.asp) or call/e-mail

Jewel Thompson at (916) 551-2061/[jthompson@cmanet.org](mailto:jthompson@cmanet.org) for more information.

**CMA's 10<sup>th</sup> Annual California Health Care Leadership Academy** takes place April 13-15<sup>th</sup> in Monterey. Learn what you need to know now about the latest trends affecting medical practice. There will also be practice management workshops for physicians and office staff. For more information and to register, visit [www.cmanet.org/leadership](http://www.cmanet.org/leadership).

### ***NHIC/Medicare, DHS/MediCal, & Private Payors***

*[Editor's Note: ANCO communicates regularly with National Heritage Insurance Company (NHIC) that administers Medicare in California and the Department of Health Services (DHS) that administers MediCal in California.]*

**NHIC/Medicare's revised ESA (EPO) *Local Coverage Determination* (LCD), or coverage policy, was effective April 2<sup>nd</sup>.** Access the revised policy via the ANCO website at [www.anco-online.org](http://www.anco-online.org). In summary:

1. J0881/J0885 are covered for anemia of cancer chemotherapy. Use 284.8 as the primary diagnosis; use E933.1 as the secondary diagnosis. You may (it is optional for NHIC/Medicare) specify the underlying cancer diagnosis under treatment. Please consider use of the cancer diagnosis carefully, especially since Medicare secondary payers may not have yet updated their coverage policies and coding/billing instructions. Coverage for this diagnosis is allowed up to 120 days following the end of treatment.
2. J0881/J0885 are covered for multiple myeloma (MM) and myelodysplastic syndromes (MDS) under anemia of bone marrow dysfunctions not under treatment with chemotherapy. Use the ICD-9 diagnosis code for MM or MDS as the primary diagnosis code.
3. J0881/J0885 are no longer covered for anemia of malignancy.

In September 2006, CMS announced that it would implement the **revised Form CMS-1500** (08-05) on January 1<sup>st</sup>, 2007 with dual acceptability of both versions until March 31<sup>st</sup>,

2007. CMS further announced that beginning April 1<sup>st</sup>, 2007, the only acceptable version of the form would be the Form CMS-1500 (08-05) and that the prior version, Form CMS-1500 (12-90), would be rejected. It has recently come to CMS's attention that there are incorrectly formatted versions of the revised form being sold by print vendors, specifically the *Government Printing Office* (GPO). Therefore, *CMS has decided to extend the acceptance period of the Form CMS-1500 (12-90) version beyond the original April 1<sup>st</sup>, 2007 deadline.* Medicare contractors will be directed to continue to accept the Form CMS-1500 (12-90) until notified by CMS. And, NHIC/Medicare has announced that it will be able to process claims submitted on incorrectly formatted CMS-1500 forms while physicians are obtaining corrected forms. The best way to identify badly formatted forms is to look at the upper right-hand corner of the form. If the tip of the red arrow above the vertically stacked word "CARRIER" is touching or close to touching the top edge of the form, then the form is not printed to specifications. There should be approximately a quarter of an inch between the tip of the arrow and the top edge of the paper on properly formatted forms. Please note that this issue involves the paper claim form only and does not affect the NPI implementation date.

The *Medicare B Resource* (March 2007) is available online at [www.medicarenhic.com/news/provider\\_news/mbr\\_mar07.pdf](http://www.medicarenhic.com/news/provider_news/mbr_mar07.pdf).

Visit [www.medicarenhic.com/cal\\_prov/updates.shtml](http://www.medicarenhic.com/cal_prov/updates.shtml) to learn the **latest information** (updated weekly) **from NHIC/Medicare**. Updates are also posted on ANCO's WebLog (at [www.anco-online.org/news/index.html](http://www.anco-online.org/news/index.html); under *California News*).

## EDUCATION

[*Editor's Note:* ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

### ***ANCO 2007 Annual Meeting: Be Prepared!***

ANCO's 2007 *Annual Meeting: Be Prepared!* will take place on Friday, June 29<sup>th</sup>-Saturday, June 30<sup>th</sup>, at the *Hyatt Vineyard Creek Hotel & Spa* in Santa Rosa. The meeting announcement

(including agenda/faculty, housing information, and registration form) is attached to this edition of the *ANCO FAX News* and available at [www.anco-online.org/annmtg2007.html](http://www.anco-online.org/annmtg2007.html). Copies are being mailed on April 6<sup>th</sup>.

### ***ANCO Legislative/Regulatory Update at ASCO's Best of ASCO 2007***

ASCO's *Best of ASCO 2007* will take place on July 20<sup>th</sup>-21<sup>st</sup> in San Francisco. *Best of ASCO* features premier abstracts from the *ASCO Annual Meeting* and offers CME opportunities for attendees. ANCO's *ASCO Highlights 2007* will not be organized in lieu of *Best of ASCO 2007* which we encourage all members to attend. For additional information, visit [www.asco.org/boa2007](http://www.asco.org/boa2007). An ANCO legislative/regulatory update with Joseph Bailes, M.D., will take place at *Best of ASCO* on the evening of July 19<sup>th</sup>! Plan on arriving early for *Best of ASCO* and attending the ANCO event. Watch for an announcement in the near future.

### ***Additional Education Meetings***

Other meetings of possible interest to ANCO member practices are:

April 12-13<sup>th</sup>  
*Achieving Efficient Practice Operations*  
Medical Group Management Association  
New Orleans

April 12-14<sup>th</sup>  
*31<sup>st</sup> Annual Symposium*  
American Society of Breast Disease  
San Francisco

April 14-18<sup>th</sup>  
*98<sup>th</sup> Annual Meeting*  
American Association for Cancer Research  
Los Angeles

April 15-16<sup>th</sup>  
*Implementing Best Practices of Successful Medical Groups*  
Medical Group Management Association  
New Orleans

April 15-17<sup>th</sup>  
*2007 Conference*  
Medical Group Management  
Association/Administrators in

Oncology/Hematology  
Austin

April 17<sup>th</sup>, May 15<sup>th</sup>, & June 19<sup>th</sup>  
*The 5<sup>th</sup> Annual Cancer Survivorship Series: Living With, Through, and Beyond Cancer*  
CancerCare  
Telephone Education Workshop

April 18<sup>th</sup>  
*Medical Update on Ovarian Cancer*  
CancerCare  
Telephone Education Workshop

April 24-28<sup>th</sup>  
*ONS Congress*  
Oncology Nursing Society  
Las Vegas

April 25<sup>th</sup>, June 28<sup>th</sup>  
*Living with Colorectal Cancer*  
CancerCare  
Telephone Education Workshop

May 2<sup>nd</sup>-4<sup>th</sup>  
*Annual Conference*  
Association of Oncology Social Work  
Portland, OR

May 6-9<sup>th</sup>  
*Spring Conference*  
California Hospice Foundation  
Reno

May 23<sup>rd</sup>, June 20<sup>th</sup>  
*Chemotherapy Related Anemia: Taking a Step Forward*  
CancerCare  
Telephone Education Workshop

June 1<sup>st</sup>-5<sup>th</sup>  
*2007 Annual Meeting*  
American Society of Clinical Oncology  
Chicago

June 21<sup>st</sup>  
*Breast Cancer Update from the ASCO 2007 Annual Meeting*  
CancerCare  
Telephone Education Workshop

June 25<sup>th</sup>-26<sup>th</sup>  
*8<sup>th</sup> Annual Patient Congress*  
Patient Advocate Foundation  
Washington, D.C.

Please contact the ANCO office for more information about these meetings.

## MEMBERSHIP RESOURCES & BENEFITS

### *Benefits*

ANCO continues to seek ways to make membership more beneficial. The Board constantly identifies, reviews, and approves of additional membership benefits. In addition to the benefits derived from its advocacy, educational, and information dissemination activities, ANCO members also benefit from group purchasing activities and value added services from a number of vendors, including:

- **California Oncology Consortium (COC) Group Purchasing Organization (GPO).** The COC GPO has preferred vendor agreements and discounted pricing with *International Oncology Network (ION)/Oncology Supply (OS)*, *McKesson Specialty Oncology Services* (formerly *National Oncology Alliance* or NOA), and OTN. Contact your local ION/OS (Doug Storer at (650) 219-9282 or douglas.storer@iononline.com; or Paul Sullivan at (602) 391-9166 or paul.sullivan@iononline.com), McKesson/NOA (Scot Wagner at (866) 466-2462 or swagner@noainc.com; or Patrick Walsh at (415) 793-8736 or patrick.walsh@mckesson.com), or OTN (Jennifer Semanik at (415) 497-2750 or Tony Policani at (509) 995-0280 or anthony.policoni@otnnet.com) representatives for more information.
- **Oncology Pharmaceutical Services (OPS)**, a division of *US Oncology*. Contact Sean Taylor at (415) 235-4673 or sean.taylor@usoncology.com for more information.
- **Onmark**, OTN's preferred group purchasing organization. Contact Monique Weston at (650) 871-2108 or monique.weston@onmarkservices.com for more information.
- **IntrinsiQ's IntelliDose Discount Program** makes *IntelliDose*, a clinical

oncology software solution, available to ANCO members at a significant discount. In addition, ancillary products/services, and maintenance fees will also be discounted for ANCO member practices. Contact Kris Beinder at *IntrinsiQ* directly at (800) 565-2279, x151 or [kbeinder@intrinsiq.com](mailto:kbeinder@intrinsiq.com) for more information about *IntrinsiQ Research* and *IntelliDose* or visit [www.intrinsiq.com](http://www.intrinsiq.com).

**McKesson Specialty Oncology Services** has extended its reimbursement call-in series. The next *Oncology Update 2007* call-in program will take place on April 25<sup>th</sup> at 12PM. Visit [www.noainc.com](http://www.noainc.com) for more information.

The *Oncology Pharmaceutical Services (OPS)* webcast entitled *Marketing Your Practice* is available at [www.opspharmacist.com/opesarchives](http://www.opspharmacist.com/opesarchives). OPS invites ANCO members to a webcast entitled *Introduction to OPS* on April 12<sup>th</sup> at 12:30PM. For more information and to register visit [www.opspharmacist.com/ancowebcast](http://www.opspharmacist.com/ancowebcast), e-mail [OPS@usoncology.com](mailto:OPS@usoncology.com), or call (866) 216-5053.

*Onmark* presents *Regimen Profiler in Your Practice* via webcast on April 11<sup>th</sup> at 9AM and 26<sup>th</sup> at 12PM. *Onmark* also presents *Benchmarking Your Practice* via webcast on May 1<sup>st</sup> at 9AM and May 2<sup>nd</sup> at 12PM. Visit [www.onmarkservices.com](http://www.onmarkservices.com) (select *Events*) for more information and to enroll.

## ASSOCIATION NEWS

### *Board of Directors*

The ANCO *Board of Directors* meets regularly by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* meetings are open to individual physician members. The next regularly scheduled ANCO *Board of Directors* teleconference will take place on May 17<sup>th</sup>. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future meeting.

### *Individual Member News*

*The ANCO Directory of Members 2006* was published and mailed to ANCO physician members; nurse and office manager contacts; and, Corporate Member representatives at the end of June 2006. Additional copies are available from the ANCO office upon request. Please verify your *Directory* entry and contact the ANCO office with any corrections, additions, and/or deletions. The next *Directory* will be published in June 2007.

The following update(s) to the *Directory* should be inserted in the appropriate location(s):

### ALPHABETICAL DIRECTORY OF NURSE & OFFICE MANAGER CONTACTS

#### Sandy Goldberg

110 La Casa Via, Suite 210  
Walnut Creek, CA 94598  
Telephone: (925) 939-9610  
FAX: (925) 939-9630  
[sandygoldberg@sbcglobal.net](mailto:sandygoldberg@sbcglobal.net)

### *Institutional Member News*

ANCO thanks the following **Institutional Members** for their support:

- *Stanford University Medical Oncology*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

For information on continuing medical education meetings organized by our **Institutional Members**, please visit:

- [med.stanford.edu/seminars/cme-all.jsp?qcme=on](http://med.stanford.edu/seminars/cme-all.jsp?qcme=on)
- [www.ucdmc.ucdavis.edu/cme/conferences](http://www.ucdmc.ucdavis.edu/cme/conferences)
- [www.cme.ucsf.edu/cme/index.aspx?Display=Date](http://www.cme.ucsf.edu/cme/index.aspx?Display=Date)

UCSF's *2nd International Symposium on Cancer and the Lymphovascular System* takes place at the *Hilton Hotel* in San Francisco on May 3<sup>rd</sup>-5<sup>th</sup>. Visit [www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MSU07002](http://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MSU07002) for more information.

UCSF's *Pain Management and End-of-Life Care* takes place at the *Sir Francis Drake Hotel* in San Francisco on June 7-8<sup>th</sup>. Visit [www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM07P14](http://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MDM07P14) for more information.

UCD's 8<sup>th</sup> *Annual Advances in Oncology* takes place at the *Hyatt Regency* in Sacramento on October 20<sup>th</sup>.

The 9<sup>th</sup> *Annual UCSF/UCD Thoracic Oncology Conference* takes place in San Francisco on November 17<sup>th</sup>. Visit [www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MSU07004](http://www.cme.ucsf.edu/cme/CourseDetail.aspx?coursenumber=MSU07004) for more information.

### Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to grow and expand its services for the hematology/oncology community in Northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AMGEN • APPI/Abraxis Oncology  
AstraZeneca  
Bayer Oncology/Onyx Pharmaceuticals  
biogenIDEC  
Bristol-Myers Squibb Oncology  
Cephalon Oncology • Clariant Diagnostics  
Enzon Pharmaceuticals  
Genentech BioOncology  
Genotope Corporation • Genomic Health  
GlaxoSmithKline  
International Oncology Network  
Lash Group Healthcare Consultants  
Lilly Oncology • Matrix Oncology  
McKesson Specialty Oncology Services  
MedImmune Oncology • MGI Pharma  
Millennium • Novartis Oncology  
Oncology Pharmaceutical Services  
Oncology Supply • Onmark  
Ortho Biotech • OSI Pharmaceuticals • OTN  
Pfizer Oncology • Pharmion  
Roche Oncology • Sanofi Aventis Oncology  
Schering-Plough Oncology • SuperGen*

**Genomic Health** informs ANCO that *Blue Shield of California* has instituted a positive

coverage policy for **Oncotype DX**. The use of Oncotype DX gene expression profiling for predicting recurrence of breast cancer when used in deciding on chemotherapy, is considered medically necessary for women newly diagnosed with Stage 1 or 2 node-negative breast cancer who are either 1) estrogen receptor positive and HER2 receptor positive with a tumor of 1cm or less or 2) estrogen receptor positive and HER2 receptor negative with any size tumor.

### Publications, Services, & Surveys

ASCO) has updated its 2004 **clinical practice guideline to guide oncologists on best practices for the initial management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer**. The new guideline is being published in the April 2<sup>nd</sup> issue of the *Journal of Clinical Oncology* ([www.jco.org](http://www.jco.org)).

### Membership Dues for 2007

**Third notices of membership renewal were mailed the week of April 2<sup>nd</sup>. Return your 2007 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members 2007*.** Be sure to provide ANCO with the name(s) of office and/or nurse manager contact(s). Those not renewing their membership by June 1<sup>st</sup> will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you did not receive or misplaced your membership dues renewal notice.

ANCO seeks new members. **All members of a practice should join ANCO.** Provide the ANCO office with the names and addresses of colleagues you would like invited to join ANCO.

**A larger ANCO is a stronger ANCO!**